Renaissance Technologies - SYROS PHARMACEUTICALS INC ownership

SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 77 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$413,000
-57.6%
429,013
-47.6%
0.00%
-100.0%
Q1 2022$975,000
+3.6%
818,962
+844.6%
0.00%0.0%
Q4 2020$941,000
+51.5%
86,700
+48.7%
0.00%0.0%
Q2 2020$621,000
-30.4%
58,300
-54.8%
0.00%0.0%
Q4 2019$892,000
-70.0%
129,085
-55.0%
0.00%
-66.7%
Q3 2019$2,975,000
+8.0%
286,600
-3.6%
0.00%
+50.0%
Q2 2019$2,754,000
+36.7%
297,400
+34.9%
0.00%0.0%
Q1 2019$2,015,000
+189.9%
220,500
+76.8%
0.00%
+100.0%
Q4 2018$695,000
+106.2%
124,700
+340.6%
0.00%
Q3 2018$337,000
-80.0%
28,300
-82.8%
0.00%
-100.0%
Q2 2018$1,684,000
+58.4%
164,900
+128.4%
0.00%0.0%
Q3 2017$1,063,000
+144.9%
72,200
+167.4%
0.00%0.0%
Q2 2017$434,00027,0000.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 3,139,895$23,486,0004.50%
Samsara BioCapital, LLC 2,189,199$14,769,0002.72%
Bain Capital Life Sciences Investors, LLC 5,785,036$43,272,0002.45%
Omega Fund Management, LLC 1,562,500$11,688,0001.11%
Flagship Pioneering Inc. 2,938,494$21,980,0000.35%
EcoR1 Capital, LLC 1,000,000$7,480,0000.33%
Altium Capital Management LP 126,702$948,0000.26%
Nikko Asset Management Americas, Inc. 5,042,009$37,714,0000.18%
Artal Group S.A. 1,025,000$7,667,0000.14%
Orbimed Advisors 1,837,500$13,745,0000.13%
View complete list of SYROS PHARMACEUTICALS INC shareholders